drugset / Trial / NCT03088527
Phase 1, First-in-Human Study of RAD140 in Postmenopausal Women With Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
The primary purpose of this study is to evaluate the clinical safety profile, tolerability, and pharmacokinetic (PK) characteristics of RAD140 in hormone receptor positive breast cancer.
Timeline
- Start
- 2017-10-23
- Primary completion
- 2020-08-28
- Completion
- 2020-09-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RAD140 | Small molecule | — | Oral |